Grass allergy sufferers wanted for Lundbeck phase I antibody study

In a new phase I study, Lundbeck will test the safety of an antibody it acquired in 2019.

Photo: Thomas Borberg

Recruitment has been initiated for a new phase I study designed to test the safety of a once-monthly injection treatment with the antibody Lu AG09222 in patients with grass pollen allergy, according to a filing on the database Clinical Trials, which collects information about research studies.

Lundbeck does not report any therapeutic targets for the phase I study in the study description, however, allergies and migraines are known to be connected, the latter of which has been a big focus area of Lundbeck ever since it acquired Alder Therapeutics in 2019. In the takeover, Lundbeck also gained access to the preventive migraine treatment Vyepti.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs